Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ibrance (palbociclib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Amgen, Pfizer

Drug class:

CDK4/6 inhibitor

Related drugs:

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1
No biomarker	Liposarcoma	No biomarker	Liposarcoma	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: A2 - Guideline palbociclib Resistant : A2	palbociclib Resistant: A2 - Guideline palbociclib Resistant : A2
CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER mutation	Breast Cancer	ER mutation	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
PLK1 overexpression	Hormone Receptor Positive Breast Cancer	PLK1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B